SCHEMBL3969747

SCHEMBL3969747

O=C1Nc2cc(Cl)ccc2C1(Cc1ccccc1)c1cccc(Cl)c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MDM2 Q00987 10/20 0.70
TP53 P04637 9/20 0.70
PGR P06401 3/20 0.48
PDE4A P27815 1/20 0.43
PDE4B Q07343 1/20 0.43
PDE4C Q08493 1/20 0.43
PDE4D Q08499 1/20 0.43
ADAM17 P78536 1/20 0.41
MAPT P10636 2/20 0.40
HTR6 P50406 2/20 0.38
HTR1A P08908 1/20 0.38
DRD1 P21728 1/20 0.38
HTR2A P28223 1/20 0.38
HTR7 P34969 1/20 0.38
MAOB P27338 1/20 0.38
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C9 P11712 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3967825 0.90 MDM2 (0.60) MDM2TP53PGRPDE4APDE4B
SCHEMBL3968204 0.87 MDM2 (0.88) MDM2TP53PGRPDE4APDE4B
SCHEMBL3968966 0.84 MDM2 (0.70) MDM2TP53PGRPDE4APDE4B
SCHEMBL3968099 0.83 MDM2 (1.00) MDM2TP53PGRPDE4APDE4B
SCHEMBL3968096 0.83 MDM2 (1.00) MDM2TP53PGRPDE4APDE4B
SCHEMBL3962261 0.82 MDM2 (0.70) MDM2TP53PGRPDE4APDE4B
SCHEMBL3969840 0.82 MDM2 (0.70) MDM2TP53PGRPDE4APDE4B
SCHEMBL3964604 0.81 MDM2 (0.86) MDM2TP53PGRPDE4APDE4B
SCHEMBL3967431 0.81 MDM2 (0.66) MDM2TP53PGRPDE4APDE4B
SCHEMBL3964752 0.81 MDM2 (0.94) MDM2TP53PGRPDE4APDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7576082-B2 Oxindole derivatives HOFFMAN-LA ROCHE INC. (US) 2009-08-18 US disclosed
US-7576082-B2 Oxindole derivatives HOFFMAN-LA ROCHE INC. (US) 2009-08-18 US disclosed
US-7576082-B2 Oxindole derivatives HOFFMAN-LA ROCHE INC. (US) 2009-08-18 US disclosed
EP-1896412-A2 OXINDOLE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2008-03-12 EP disclosed
WO-2006136606-A2 OXINDOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2006-12-28 WO disclosed
WO-2006136606-A2 OXINDOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2006-12-28 WO disclosed
US-20060293319-A1 Oxindole derivatives LUK KIM-CHUN 2006-12-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060293319-A1 Oxindole derivatives CCNI, OGFR, MKI67 MDM2 759/4885TP53 96/4885PGR 933/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.